Nov 30, 2021 | by Kelly Prymicz, Commentary, Specialty Drug Management
If you’re a plan sponsor, you’re probably familiar with the drug Humira. That’s undoubtedly because it appears toward the top of your list of costliest drugs. Well, that might change soon. Or maybe not. It’s tough to tell. (more…)
Oct 5, 2020 | by Kelly Prymicz, Commentary, Specialty Drug Management
When I was working in a large health system’s patient safety department, we empowered patients to be their own advocate. If something didn’t seem right, feel right, or had not been explained clearly, we encouraged them to speak up.
This is something I’ve been thinking about quite a bit lately as mega high-priced cell and gene therapies make their way on the market with only scant acknowledgement from plan sponsors. As evidenced by our frequent posts, webinars, and pretty much sharing with anyone who will listen (sorry Amazon delivery guy), our firm has been closely ― some would say obsessively ― following these emerging therapies. (more…)